Thermo Fisher Scientific (TMO) Cash & Equivalents (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Cash & Equivalents for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 11.19% year-over-year to $4.1 billion; the trailing twelve-month figure through Jun 2026 stood at $4.1 billion (down 11.19% YoY), and the FY2025 full-year result was $9.9 billion, up 145.75% from the prior year.
• Cash & Equivalents advanced to $4.1 billion in Q2 2026 per TMO's latest filing, from $3.3 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $9.9 billion in Q4 2025 and bottomed at $1.9 billion in Q3 2022.
• Historically, Cash & Equivalents has averaged $4.8 billion across 5 years, with a median of $4.1 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 75.73% in 2022, then surged 145.75% in 2025.
• Over 5 years, Cash & Equivalents stood at $8.5 billion in 2022, then slipped by 5.24% to $8.1 billion in 2023, then plunged by 50.37% to $4.0 billion in 2024, then surged by 145.75% to $9.9 billion in 2025, then plunged by 58.75% to $4.1 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.1 billion, $3.3 billion, and $9.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.